What is Immatics?
Immatics is at the forefront of cancer immunotherapy, combining the discovery of crucial cancer targets with the development of precise T cell receptors. This integrated approach aims to elicit a potent and specific T cell response against these targets, forming the bedrock of its innovative pipeline. The company's expertise extends to both Adoptive Cell Therapies and TCR Bispecifics, positioning it to offer new therapeutic avenues for patients battling cancer. Furthermore, Immatics leverages its deep know-how through strategic partnerships with leading global pharmaceutical entities, amplifying its reach and impact in the fight against cancer.
How much funding has Immatics raised?
Immatics has raised a total of $392.5M across 8 funding rounds:
Series A
$9.9M
Series B
$52.1M
Series C
$71.2M
Series D
$16.3M
Other Financing Round
$30M
Other Financing Round
$58M
Share Placement
$35M
Private Equity
$120M
Series A (2004): $9.9M with participation from 3i Group, VINCI CAPITAL, EMBL Ventures, and Merifin Capital
Series B (2007): $52.1M led by 3i Group, DH Capital, KfW, NTEC, and OH Beteiligungen
Series C (2010): $71.2M supported by AT Impf, dievini Hopp Biotech Holding, and MIG Capital
Series D (2013): $16.3M featuring Wellington Partners, MIG Funds, and dievini Hopp BioTech
Other Financing Round (2017): $30M backed by Amgen
Other Financing Round (2017): $58M with participation from Amgen, AT Impf, and dievini Hopp Biotech Holding
Share Placement (2023): $35M led by Bristol-Myers Squibb
Private Equity (2023): $120M supported by Moderna
Key Investors in Immatics
Moderna
Moderna is a pioneer in mRNA medicine, dedicated to transforming the creation and delivery of treatments and vaccines. Their investment in Immatics highlights a strategic interest in innovative therapeutic platforms beyond their core mRNA technology.
Amgen
Amgen Inc. is a leading biotechnology company focused on discovering, developing, and delivering innovative human therapeutics. Their backing of Immatics suggests a strategic alignment with advanced cell therapy approaches in oncology.
Bristol-Myers Squibb
Bristol-Myers Squibb is a global biopharmaceutical company committed to discovering, developing, and delivering innovative medicines that help patients prevail over serious diseases. Their investment indicates a strategic interest in novel cancer immunotherapies and cell-based treatments.
What's next for Immatics?
With the recent major strategic investment, Immatics is poised for accelerated growth and development. The company's focus on pioneering T cell receptor-based therapies suggests a strategic direction towards expanding its clinical trial pipeline and potentially scaling up manufacturing capabilities. This infusion of capital is likely to bolster research and development efforts, enabling Immatics to further refine its therapeutic candidates and explore new target antigens. The company's commitment to delivering the power of T cells indicates a forward-looking strategy aimed at unlocking new treatment paradigms for a wide range of cancers, solidifying its position as a key player in the advanced oncology space.
See full Immatics company page
